Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies - Additional Information (Detail)

v3.4.0.3
Commitments and Contingencies - Additional Information (Detail)
 1 Months Ended 3 Months Ended 4 Months Ended
Aug. 01, 2015
ft²
Apr. 24, 2015
USD ($)
Feb. 29, 2016
USD ($)
Employee
Feb. 28, 2015
USD ($)
ft²
Dec. 31, 2009
USD ($)
Mar. 31, 2016
USD ($)
Mar. 31, 2015
USD ($)
Apr. 24, 2015
USD ($)
Mar. 31, 2016
CAD
Dec. 31, 2015
USD ($)
May. 14, 2015
Feb. 01, 2015
USD ($)
Other Commitments [Line Items]                        
Expiration of operating lease agreement           2016-09            
Additional office space | ft² 2,245                      
Consolidated rent and facilities expense           $ 100,000 $ 500,000          
Lease termination agreement, additional fee payable       $ 1,300,000                
Lease termination liability           1,250,000       $ 1,250,000    
Indemnification obligations           0            
Expenses related to indemnification issues           0            
Reduction in workforce | Employee     11                  
Percentage of workforce reduction     27.00%                  
Expenses on workforce reduction     $ 400,000                  
Vancouver, Canada [Member]                        
Other Commitments [Line Items]                        
Future minimum annual lease payments under the lease           43,000            
Grosvenor International Limited [Member]                        
Other Commitments [Line Items]                        
Area of office space leased | ft²       11,526                
Expiration date of option to lease additional area of office space       Aug. 01, 2015                
Lease expiration date       Apr. 30, 2018                
Optional lease renewal       3 years                
Monthly base rent commencement date       May 01, 2015                
Lessee's share of property tax percentage.       17.00%                
Lease agreement, construction allowance receivable                       $ 100,000
Deposit amount under lease agreement                       $ 200,000
Grosvenor International Limited [Member] | Maximum [Member]                        
Other Commitments [Line Items]                        
Monthly base rent       $ 20,000                
Grosvenor International Limited [Member] | Minimum [Member]                        
Other Commitments [Line Items]                        
Monthly base rent       $ 18,000                
BMR-217TH Place LLC [Member]                        
Other Commitments [Line Items]                        
Lease termination agreement, date of termination       Mar. 01, 2015                
Letter of credit drawn to pay deferred state sales tax       $ 100,000                
Letter of credit terminated       200,000                
Terminated lease       500,000                
Lease termination liability           1,300,000            
BMR-217TH Place LLC [Member] | Termination Fee [Member]                        
Other Commitments [Line Items]                        
Lease termination agreement, fee payable       2,000,000                
BMR-217TH Place LLC [Member] | Minimum [Member]                        
Other Commitments [Line Items]                        
Amount of funding to raise that would trigger payment of additional termination fee       $ 20,000,000                
Collaborative Arrangement [Member] | Teva Pharmaceutical Industries Ltd. [Member]                        
Other Commitments [Line Items]                        
Proceeds from advance reimbursement research and development               $ 27,000,000        
Hold-back amount and third-party expenses deducted from advanced reimbursement payment   $ 3,800,000           3,800,000        
Hold-back amount deducted from advanced reimbursement payment   3,000,000           3,000,000        
Third-party expenses deducted from advanced reimbursement payment               $ 800,000        
Maximum cost exposure if third-party agreements discovered after the termination date           100,000            
Collaboration agreement aggregate amount         $ 50,000,000              
Gross proceeds           10,000,000            
Direct and indirect costs incurred           $ 30,000,000            
Collaborative Arrangement [Member] | University of British Columbia [Member] | Maximum [Member]                        
Other Commitments [Line Items]                        
Milestone payments | CAD                 CAD 1,600,000      
Collaborative Arrangement [Member] | Ionis Pharmaceuticals Inc. [Member]                        
Other Commitments [Line Items]                        
Collaboration agreement aggregate amount   $ 23,200,000                    
Net proceed from collaboration agreement amount, requested payment percentage                     20.00%  
Hold-back amount, requested payment percentage                     30.00%  
Lawsuit filing date           January 5, 2016            
Amount due to Ionis for reimbursement for research and development activities           $ 0            
Range of each product line           10 years            
Milestone payment due           $ 20,000,000            
Period of milestone payment           21 days            
Reserve for contingency of non payment of non-royalty milestone amount           $ 20,000,000            
Milestone payment made           10,000,000            
Balance amount of milestone payment           10,000,000            
Collaborative Arrangement [Member] | Ionis Pharmaceuticals Inc. [Member] | Maximum [Member]                        
Other Commitments [Line Items]                        
Milestone payments           7,750,000            
Collaborative Arrangement [Member] | Ionis Pharmaceuticals Inc. [Member] | Minimum [Member]                        
Other Commitments [Line Items]                        
Damages arise due to termination of agreement           $ 10,000,000